Great Basin Scientific (GBSN) Receiving Somewhat Favorable News Coverage, Report Finds
Headlines about Great Basin Scientific (NASDAQ:GBSN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Great Basin Scientific earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.1959014929014 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Great Basin Scientific (GBSN) traded down $0.04 during trading on Friday, hitting $0.09. The stock had a trading volume of 922,782 shares.
Great Basin Scientific Company Profile
Great Basin Scientific, Inc is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C.
Receive News & Ratings for Great Basin Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Great Basin Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.